183 related articles for article (PubMed ID: 33935572)
1. Magnetic field potential effects on the doxorubicin therapeutic activity in Ehrlich tumor growth.
Ghannam MM; Al-Otaibi HA; Alanazy ES; Elnagar D; Fouad AR; AlAyed MS; Aly AA
Saudi J Biol Sci; 2021 Apr; 28(4):2566-2574. PubMed ID: 33935572
[TBL] [Abstract][Full Text] [Related]
2. Ehrlich tumor inhibition using doxorubicin containing liposomes.
Elbialy NS; Mady MM
Saudi Pharm J; 2015 Apr; 23(2):182-7. PubMed ID: 25972739
[TBL] [Abstract][Full Text] [Related]
3. Effect of hesperidin on mice bearing Ehrlich solid carcinoma maintained on doxorubicin.
Khedr NF; Khalil RM
Tumour Biol; 2015 Dec; 36(12):9267-75. PubMed ID: 26099723
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumour activity of doxorubicin and simvastatin combination loaded nanoemulsion treatment against a Swiss albino mouse model of Ehrlich ascites carcinoma.
Alkreathy HM; Alkhatib MH; Al Musaddi SA; Balamash KSA; Osman NN; Ahmad A
Clin Exp Pharmacol Physiol; 2019 May; 46(5):496-505. PubMed ID: 30724380
[TBL] [Abstract][Full Text] [Related]
5. The synergistic effect between vanillin and doxorubicin in ehrlich ascites carcinoma solid tumor and MCF-7 human breast cancer cell line.
Elsherbiny NM; Younis NN; Shaheen MA; Elseweidy MM
Pathol Res Pract; 2016 Sep; 212(9):767-77. PubMed ID: 27493101
[TBL] [Abstract][Full Text] [Related]
6. Enhanced anticancer effect and reduced toxicity of doxorubicin in combination with thymoquinone released from poly-N-acetyl glucosamine nanomatrix in mice bearing solid Ehrlish carcinoma.
El-Ashmawy NE; Khedr EG; Ebeid EM; Salem ML; Zidan AA; Mosalam EM
Eur J Pharm Sci; 2017 Nov; 109():525-532. PubMed ID: 28890201
[TBL] [Abstract][Full Text] [Related]
7. Anti-cancer and cardioprotective effects of indol-3-carbinol in doxorubicin-treated mice.
Adwas AA; Elkhoely AA; Kabel AM; Abdel-Rahman MN; Eissa AA
J Infect Chemother; 2016 Jan; 22(1):36-43. PubMed ID: 26603425
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of polydopamine as a new and biocompatible coating of magnetic nanoparticles for delivery of doxorubicin in mouse breast adenocarcinoma.
Zavareh S; Mahdi M; Erfanian S; Hashemi-Moghaddam H
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1073-1084. PubMed ID: 27752764
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
[TBL] [Abstract][Full Text] [Related]
10. [Targeting therapy of magnetic doxorubicin liposome in nude mice bearing colon cancer].
Zhou PH; Yao LQ; Qin XY; Shen XZ; Liu YS; Lu WY; Yao M
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2073-6. PubMed ID: 14703420
[TBL] [Abstract][Full Text] [Related]
11. The activity against Ehrlich's ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticle with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate.
Ray L; Kumar P; Gupta KC
Biomaterials; 2013 Apr; 34(12):3064-76. PubMed ID: 23357370
[TBL] [Abstract][Full Text] [Related]
12. Inhibition by oral N-acetylcysteine of doxorubicin-induced clastogenicity and alopecia, and prevention of primary tumors and lung micrometastases in mice.
D'Agostini F; Bagnasco M; Giunciuglio D; Albini A; De Flora S
Int J Oncol; 1998 Aug; 13(2):217-24. PubMed ID: 9664114
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin uptake in ascitic lymphoma model: resistance or curability is governed by tumor cell density and prolonged drug retention.
Zaleskis G; Garberytė S; Pavliukevičienė B; Valinčius G; Characiejus D; Mauricas M; Kraśko JA; Žilionytė K; Žvirblė M; Pašukonienė V
J Cancer; 2020; 11(22):6497-6506. PubMed ID: 33046971
[No Abstract] [Full Text] [Related]
14. Synergistic efficacy of γ-radiation together with gallium trichloride and/or doxorubicin against Ehrlich carcinoma in female mice.
Kandil E; Aziz NA
Tumour Biol; 2016 Feb; 37(2):1825-34. PubMed ID: 26318299
[TBL] [Abstract][Full Text] [Related]
15. Polydatin gold nanoparticles potentiate antitumor effect of doxorubicin in Ehrlich ascites carcinoma-bearing mice.
Samra YA; Abdelghany AM; Zaghloul RA
J Biochem Mol Toxicol; 2021 Oct; 35(10):e22869. PubMed ID: 34339076
[TBL] [Abstract][Full Text] [Related]
16. Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy.
Zhang P; Li J; Ghazwani M; Zhao W; Huang Y; Zhang X; Venkataramanan R; Li S
Biomaterials; 2015 Oct; 67():104-14. PubMed ID: 26210177
[TBL] [Abstract][Full Text] [Related]
17. Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice.
Murugesan K; Srinivasan P; Mahadeva R; Gupta CM; Haq W
Int J Nanomedicine; 2020; 15():10547-10559. PubMed ID: 33414637
[TBL] [Abstract][Full Text] [Related]
18. The effects of β-caryophyllene oxide and trans-nerolidol on the efficacy of doxorubicin in breast cancer cells and breast tumor-bearing mice.
Hanušová V; Caltová K; Svobodová H; Ambrož M; Skarka A; Murínová N; Králová V; Tomšík P; Skálová L
Biomed Pharmacother; 2017 Nov; 95():828-836. PubMed ID: 28903178
[TBL] [Abstract][Full Text] [Related]
19. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
20. Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine.
Gupta A; Miki K; Xu M; Yamamoto N; Moossa AR; Hoffman RM
Anticancer Res; 2003; 23(2B):1181-8. PubMed ID: 12820369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
